Interstitial lung lesion in systemic scleroderma (literature review and personal observation)
https://doi.org/10.18093/0869-0189-2020-30-1-102-108
Abstract
Interstitial lesion is one of the most common lung pathologies in patients with systemic scleroderma (SS) In most cases, interstitial lung disease (ILD) is formed during the detailed clinical picture of SS, but it can manifest from interstitial lung disease, which significantly complicates early nosological diagnosis. Patterns of non-specific and common interstitial pneumonia are most often found among the variants of interstitial lung lesion at SS Clinical manifestations of ILD-SS are non-specific and vary significantly between patients from asymptomatic to rapidly progressing respiratory failure. Early diagnosis of subclinical interstitial pulmonary lesion at SS is carried out using high-resolution computed tomography. Active immunosuppressive therapy is required for timely diagnosis of progressive forms of ILD-SS The presented clinical study demonstrates a case of late diagnosis of ILD-SS
About the Authors
M. S. Nashatyreva
Irkutsk State Medical Academy of Postgraduate Education – Branch Campus of Irkutsk State Medical Academy of Postgraduate Training
Russian Federation
Russian Federation
Mariya S. Nashatyreva, Postgraduate student
mkr Yubileynyy 100, Irkutsk, 664079
tel.: (3952) 22-85-77
I. N. Trofimenko
Irkutsk State Medical Academy of Postgraduate Education – Branch Campus of Irkutsk State Medical Academy of Postgraduate Training
Russian Federation
Russian Federation
Irina N. Trofimenko, Doctor of Medicine, Associate Professor, Department of Clinical Allergology and Pulmonology
mkr Yubileynyy 100, Irkutsk, 664079
tel.: (9148) 77-80-96
B. A. Chernyak
Irkutsk State Medical Academy of Postgraduate Education – Branch Campus of Irkutsk State Medical Academy of Postgraduate Training
Russian Federation
Russian Federation
Boris A. Chernyak, Doctor of Medicine, Professor, Head of Department of Clinical Allergology and Pulmonology
mkr Yubileynyy 100, Irkutsk, 664079
tel.: (9025) 68-78-70
References
1. Anan'eva L.P. [Diagnosis and treatment of interstitial lung disease in scleroderma systematica]. Sovremennaya revmatologiya. 2018; 12 (2): 12–21/ DOI: 10.14412/1996-70122018-2-12-21 (in Russian).
2. Ferri C., Valentini G., Cozzi F. et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002; 81 (2): 139–153. DOI: 10.1097/00005792-200203000-00004.
3. Chowaniec M., Skoczyńska M., Sokolik R. et al. Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management. Reumatologia. 2018; 56 (4): 249–254. DOI: 10.5114/reum.2018.77977.
4. Cottin V., Brown K.K. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir. Res. 2019; 20: 13. DOI: 10.1186/s12931-019-0980-7.
5. Cappelli S., Bellando Randone S., Camiciottoli G. et al. Interstitial lung disease in systemic sclerosis: where do we stand? Eur. Respir. Rev. 2015; 24 (137): 411–419. DOI: 10.1183/16000617.00002915.
6. Varga J. Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma). UpToDate. Available at: https://www.uptodate.com/contents/clinical-manifestations-evaluation-and-diagnosis-ofinterstitial-lung-disease-in-systemic-sclerosis-scleroderma
7. Valeyre D., Duchemann B., Nunes H. et al. Interstitial lung diseases. Respiratory Epidemiology. ERS Monogr., chapter 6. 2014; 65: XIV–XVII.
8. Mathai S.C., Danoff S.K. Management of interstitial lung disease associated with connective tissue disease. Br. Med. J. 2016; 352: h6819. DOI: 10.1136/bmj.h6819.
9. Jung E., Suh C.H., Kim H.A., Jung J.Y. Clinical characteristics of systemic sclerosis with interstitial lung disease. Arch. Rheumatol. 2018; 33 (3): 322–327. DOI: 10.5606/ArchRheumatol.2018.6630.
10. Khanna D., Nagaraja V., Tseng C.H. et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosisassociated interstitial lung disease trials. Arthritis Res. Ther. 2015; 17: 372. DOI: 10.1186/s13075-015-0872-2.
11. Antoniou K.M., Margaritopoulos G., Economidou F. et al. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur. Respir. J. 2009; 33 (4): 882–896. DOI: 10.1183/09031936.00152607.
12. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972–2002. Ann. Rheum. Dis. 2007; 66 (7): 940–944. DOI: 10.1136/ard.2006.066068.
13. Rubio-Rivas M., Royo C., Simeón C.P. et al. Mortality and survival in systemic sclerosis: systematic review and metaanalysis. Semin. Arthritis Rheum. 2014; 44 (2): 208–219. DOI: 10.1016/j.semarthrit.2014.05.010.
14. Bouros D., Wells A.U., Nicholson A.G. et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 2002; 165 (12): 1581–1586. DOI: 10.1164/rccm.2106012.
15. Lesnyak V.N., Anan'eva L.P., Koneva O.A. et al. [Semiquantification image methods for assessing severity of scleroderma-associated interstitial lung disease according to computed tomography data]. Pul'monologiya. 2017; 27 (1): 41–50. DOI: 10.18093/0869-0189-2017-27-1-41-50 (in Russian).
16. Cottin V. Idiopathic interstitial pneumonias with connective tissue diseases features: a review. Respirology. 2016; 21 (2): 245–258. DOI: 10.1111/resp.12588.
17. Wells A.U., Hansell D.M., Corrin B. et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax. 1992; 47 (9): 738–742. DOI: 10.1136/thx.47.9.738.
18. Steen V.D., Conte C., Owens G.R., Medsger T.A. Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994; 37 (9): 1283–1289. DOI: 10.1002/art.1780370903.
19. Jaeger V.K., Wirz E.G., Allanore Y. et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One. 2016; 11 (10): e0163894. DOI: 10.1371/journal.pone.0163894.
20. Nihtyanova S.I., Schreiber B.E., Ong V.H. et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 2014; 66 (6): 1625–1635. DOI: 10.1002/art.38390.
21. Tashkin D.P., Elashoff R., Clements P.J. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 2006; 354 (25): 2655–2666. DOI: 10.1056/NEJMoa055120.
22. Tashkin D.P., Roth M.D., Clements P.J. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: scleroderma lung study II (SLS-II): a randomised controlled, double-blind, parallel group trial. Lancet Respir. Med. 2016; 4 (9): 708–719. DOI: 10.1016/S2213-2600(16)30152-7.
23. Huang H., Feng R., Li S. et al. A case report: The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: a CARE-compliant article. Medicine (Baltimore). 2016; 95 (27): e4113. DOI: 10.1097/MD.0000000000004113.
24. Miura Y., Saito T., Fujita K. et al. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc. Diffuse Lung Dis. 2014; 31 (3): 235–238.
25. Duarte A.C., Santos M.J., Cordeiro A. Anti-fibrotic nintedanib – a new opportunity for systemic sclerosis patients? Clin. Rheumatol. 2018; 37 (4): 1123–1127. DOI: 10.1007/s10067-017-3867-3.
26. Distler O., Brown K.K., Distler J.H.W. et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clin. Exp. Rheumatol. 2017; 35, Suppl. 106 (4): 75–81.
27. Plastiras S.C., Karadimitrakis S.P., Ziakas P.D. et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 2006; 55 (4): 598–602. DOI: 10.1002/art.22099.
28. Kallenbach J., Prinsloo I., Zwi S. Progressive systemic sclerosis complicated by diffuse pulmonary haemorrhage. Thorax. 1977; 32 (6): 767–770. DOI: 10.1136/thx.32.6.767.
29. Fischer A., du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012; 380 (9842): 689–698. DOI: 10.1016/S0140-6736(12)61079-4.
Review
For citations:
Nashatyreva M.S., Trofimenko I.N., Chernyak B.A. Interstitial lung lesion in systemic scleroderma (literature review and personal observation). PULMONOLOGIYA. 2020;30(1):102-108. (In Russ.) https://doi.org/10.18093/0869-0189-2020-30-1-102-108
Views:
3263
Email this article 